A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy

Trial Profile

A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Ponesimod (Primary)
  • Indications Graft-versus-host disease
  • Focus Pharmacodynamics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Status changed from active, no longer recruiting to discontinued.
    • 09 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
    • 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top